Lyell Wealth Management LP Has $3.38 Million Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Lyell Wealth Management LP lessened its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,930 shares of the company's stock after selling 7,750 shares during the quarter. Lyell Wealth Management LP owned approximately 0.08% of PROCEPT BioRobotics worth $3,376,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Creative Planning lifted its position in shares of PROCEPT BioRobotics by 88.9% in the third quarter. Creative Planning now owns 9,948 shares of the company's stock worth $797,000 after buying an additional 4,681 shares during the last quarter. Blue Trust Inc. raised its stake in shares of PROCEPT BioRobotics by 11.7% in the 3rd quarter. Blue Trust Inc. now owns 4,441 shares of the company's stock valued at $356,000 after acquiring an additional 466 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of PROCEPT BioRobotics by 12,919.5% in the 3rd quarter. International Assets Investment Management LLC now owns 52,078 shares of the company's stock valued at $4,172,000 after acquiring an additional 51,678 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in PROCEPT BioRobotics by 27.4% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 5,922 shares of the company's stock worth $474,000 after purchasing an additional 1,273 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in PROCEPT BioRobotics during the third quarter worth approximately $27,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, EVP Alaleh Nouri sold 28,092 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the sale, the executive vice president now directly owns 52,472 shares of the company's stock, valued at approximately $5,096,605.36. The trade was a 34.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Reza Zadno sold 26,420 shares of the stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60. Following the completion of the transaction, the chief executive officer now directly owns 179,185 shares of the company's stock, valued at approximately $17,529,668.55. The trade was a 12.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 80,935 shares of company stock worth $7,882,089. Company insiders own 17.40% of the company's stock.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded down $3.14 during midday trading on Friday, hitting $62.25. The company had a trading volume of 1,465,542 shares, compared to its average volume of 861,542. The firm has a fifty day simple moving average of $76.53 and a two-hundred day simple moving average of $79.72. The stock has a market cap of $3.25 billion, a price-to-earnings ratio of -31.92 and a beta of 1.03. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a fifty-two week low of $45.20 and a fifty-two week high of $103.81.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on PRCT shares. Morgan Stanley assumed coverage on shares of PROCEPT BioRobotics in a research report on Monday, December 2nd. They issued an "overweight" rating and a $105.00 price target on the stock. Wells Fargo & Company reiterated an "overweight" rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Truist Financial restated a "buy" rating and set a $105.00 price target (up from $95.00) on shares of PROCEPT BioRobotics in a report on Wednesday, October 30th. Finally, Jefferies Financial Group began coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They issued a "hold" rating and a $95.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).